Sat. March 13, 2010
-
Zacks.com
March 12, 2010
... addition to a decrease in the average outstanding principal balance of and a reduced interest rate on the note due to Novartis (NVS - Snapshot Report). ...
FiercePharma
March 12, 2010
Joe Jiminez, Novartis' new chief, says his experience hawking Heinz ketchup helps him manage more effectively in the pharma world. ...
Drug Store News
March 12, 2010
... stromal tumor in patients whose disease has progressed after taking or who are unable to take
Novartis' Gleevec (imatinib mesylate) and kidney
cancer. ...
Monthly Prescribing Reference
March 12, 2010
... from Roche), Fosamax (alendronate tablets and oral solution, from
Merck), and Reclast (zoledronic acid soln for IV infusion, from
Novartis).
Trading Markets (press release)
March 12, 2010
US-based companies
Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the
US District Court for the District of ...
Pharma Times
March 12, 2010
... a
cancer of the digestive system after disease progression on or for patients who are intolerant to
Novartis' Glivec (imatinib). It is a big earner, ...
Trading Markets (press release)
March 12, 2010
Ciprofloxacin dry powder inhaler (DPI) is an investigational drug-device combination that combines ciprofloxacin dry powder formulated using Novartis's ...
San Francisco Business Times
March 11, 2010
As co-chairman, Homcy also will focus on Portola's high-profile partnerships with
Novartis and
Merck & Co. Inc.
Novartis paid $75 million upfront and is ...
PR Newswire (press release)
March 11, 2010
We are particularly excited about the partnership with Novartis for hearing loss that was announced earlier this year. We look forward to continued ...
Drug Store News
March 11, 2010
The drug, formulated using
Novartis' proprietary PulmoSphere
technology, is currently in phase 2 clinical trials. The agency grants orphan drug designation ...
Motley Fool
March 11, 2010
Novartis is a Motley Fool
global Gains pick. Procter & Gamble is an Income
investor pick. Whether you like your companies big or small, dividend laden or ...
Montreal Gazette
March 11, 2010
Novartis aims to buy the rest of leading eye-care firm Alcon for $39.3 billion US to reduce reliance on ...
Trading Markets (press release)
March 11, 2010
Transgene SA has signed an exclusive option agreement with Novartis AG, a Swiss pharmaceutical company, for the development and commercialization of ...
CNNMoney.com (press release)
March 11, 2010
With this repayment, XOMA's sole long-term
debt obligation at the end of 2009 was the $13.3 million
Novartis note. This note was established to facilitate ...
TopNews United States
March 11, 2010
Popular ones include Fosamax, Roche Holding AG's Boniva, Reclast by Novartis and P&G's Actonel. In June of 2008, the FDA had specific information from all ...
Pharma Times
March 11, 2010
Novartis has signed a deal with Transgene which could give it access to the French
biotechnology firm's investigational
lung cancer vaccine. ...
Reuters
March 10, 2010
The
Novartis deal comes after Transgene told Reuters in December it was nearing a partnership for the vaccine that could also target other
cancer types and ...
CNNMoney.com (press release)
March 10, 2010
Product revenue for product shipped to Novartis is expected to be approximately $6 million to $8 million for the year, which includes approximately $4-5 ...
BNET
March 10, 2010
While the civilized world agreed long ago that firing pregnant women is wrong, it's still a matter of open debate at Novartis ...
Economic Times
March 10, 2010
... a near 10% increase over last year, made by pharmaceutical major
Novartis for its prestigious HR leadership role at Basel,
Switzerland. ...
BusinessWeek
March 10, 2010
Visudyne was developed and is marketed with
Novartis. During the quarter, QLT sold its QLT
USA unit. The company reported income from discontinued ...
FiercePharma
March 10, 2010
Swiss drugmaker
Novartis announced a $5 billion bond issue to
finance its purchase of eye-care company Alcon. Report >
Abbott Laboratories has agreed to buy ...
Trading Markets (press release)
March 10, 2010
Novartis Ag Ads (NVS) has Short Term PowerRatings at TradingMarkets. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link. ...
Ticker Magazine
March 10, 2010
Novartis and MGM led the bonds offering today and Goldman led the offering in
Euro bonds. US stocks traded higher and commodities declined in the early ...
Reuters
March 10, 2010
Worldwide Visudyne sales, which includes sales from its partner Novartis AG (NOVN.VX) dropped 17 percent to $25.4 million. The company also said it sees ...
Livemint
March 10, 2010
AP Basel,
Switzerland: Swiss drug maker
Novartis AG announced
Wednesday a $5 billion bond issue to
finance its purchase of eye-care company Alcon Inc. The ...
PharmaLive.com (press release)
March 10, 2010
Pursuant to the agreement, Transgene has granted Novartis an option to acquire an exclusive worldwide license for TG4010 and Novartis will pay Transgene a ...
Emii.com
March 10, 2010
Novartis Capital has raised $5 billion in a three-part senior notes sale, The
Wall Street Journal reports. The proceeds will be used to fund the takeover of ...
MarketWatch (press release)
March 9, 2010
global healthcare leader
Novartis is supporting the development of this community. According to the United Network for Organ Sharing, there were 23000+ ...
Motley Fool
March 9, 2010
Pfizer is an Inside Value choice.
Novartis is a
global Gains pick. The Fool owns shares of
GlaxoSmithKline and has a disclosure policy.
Reuters
March 9, 2010
Issue: The Swiss pharmaceutical firm plans a $4 billion senior bond in three parts: a three-year, a five-year and a 10-year, an official at one of the
banks ...
PR Newswire (press release)
March 9, 2010
Mary Kate Breeden worked as a pharmaceutical sales representative for Novartis for over seven (7) years. After announcing that she was pregnant, ...
Reuters
March 9, 2010
The notes are guaranteed by
Novartis AG. The size of the deal was increased from an originally planned $4 billion.
Goldman Sachs and JP Morgan were the ...
Reuters
March 9, 2010
NEW YORK, March 9 (Reuters) -
Novartis Capital Corp on
Tuesday sold $5.0 billion of notes in a three-part sale, said a
market source familiar with the ...
Reuters
March 9, 2010
... 30-yr Baa2/BBB/BBB+ BAS/CITI 3/8 Novartis Capital $TBA 3-yr Aa2/AA-/AA GS/JPM Novartis Capital $TBA 5-yr Aa2/AA-/AA GS/JPM Novartis Capital $TBA 10-yr ...
Proactive Investors UK
March 9, 2010
UK based stem-cell biotech company, Epistem (LSE: EHP) revealed the commercial progress being made through its partnership with
Novartis as it reported a ...
BNET
March 9, 2010
Even a licensing deal with Novartis (NVS), however, is unlikely to dramatically alter doctors' prescribing habits. Fanapt (iloperidone) doesn't offer any ...
Mass High Tech
March 9, 2010
By Mass High Tech staff
health care IT company PatientsLikeMe Inc. reports it is working with
Novartis AG on a section of its online health care community ...
Trading Markets (press release)
March 9, 2010
Fourth quarter 2009 revenues included $27.6 million recognized from the ZALBIN agreement with Novartis, $17.7 million recognized from sales and deliveries ...
JoongAng Daily
March 8, 2010
Korea is one of a few key emerging pharmaceutical
markets in the world, according to Peter Jager, president of
Novartis Korea.
Novartis is a multinational ...
